MiraDx, a molecular diagnostics company specializing in germline genetic testing to personalize cancer treatment, announced that a new study published in the Journal of Health Economics and Outcomes Research shows the PROSTOX ultra test provides meaningful long-term economic and quality-of-life benefits for men with localized prostate cancer undergoing stereotactic body radiation therapy.
Health Technology Insights: GE Healthcare Partners with Indonesia to Expand CT Access
PROSTOX ultra is a clinically validated genetic test that identifies patients at higher risk of late genitourinary side effects, such as urinary urgency, leakage, or discomfort, that can occur months or years after SBRT and may persist for life. By identifying patients at elevated risk, the test allows physicians and patients to make more informed treatment decisions and consider alternative therapies when necessary.
The study modeled treatment pathways comparing PROSTOX ultra to the current standard of care and found that using the test could save approximately $19,615 per patient during treatment and about $24,777 over a patient’s lifetime while providing an additional 0.24 quality-adjusted life years.
Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits
Melissa Stoppler, MD, Executive Vice President of Medical Affairs at MiraDx, stated that physicians using PROSTOX ultra are already seeing the benefit of helping patients avoid late GU toxicity and that the new results confirm the test significantly reduces long-term costs for the healthcare system.
These findings further highlight the value of integrating PROSTOX ultra into clinical decision-making for men considering SBRT for localized prostate cancer.
Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
